Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PYXS · NASDAQ · Pharmaceutical Preparations
$1.81+0.13 (+7.74%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Pyxis Oncology (PYXS) · oqro.io/stocks/PYXS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
RTW Investments, LP now owns 9.9% of PYXS as a passive investorSourceFund moves · Holdings as of Sep 30, 2026 (Q3 2026) · Filed Nov 13, 2026
Soros Fund Management disclosed a new position in PYXS for Q3 2026Source5%+ stake · Stake as of Oct 1, 2026 · Filed Oct 5, 2026
Coastlands Capital LP now owns 5.4% of PYXS as a passive investorSourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Deep Track Capital, LP no longer reported PYXS for Q4 2024SourceInsider trade · Traded Nov 26, 2024 · Filed Nov 27, 2024
CFO purchased ~$163K of PYXS shares in the open marketSourceInsider trade · Traded Nov 26, 2024 · Filed Nov 27, 2024
CFO purchased ~$11K of PYXS shares in the open marketSource